Andreas brings over 25 years of experience in the CDMO and biopharmaceutical manufacturing industry, specializing in areas like ADCs, Bioconjugates, Exosomes, recombinant Proteins, HPAPIs and Cell and Gene therapies.

​

• Accompanied more than 200 clinical projects including the commercial launch of several projects.

• Started with Sigma Aldrich (SAFC) now Merck Millipore later moved to Lonza to lead their Emerging Technology business.

• During his time at Lonza, the world’s largest Cell & Gene Therapy facility in Houston with almost 300’000 square feet, was constructed. To further expand Lonza’s Cell & Gene footprint, Pharma Cell in Europe was acquired and a strategic collaboration with Nikon in Japan was formed this allowed Lonza to support their customers and patients with global services and solutions offering. As automation technologies are a key success factor in the Cell therapy space the automation technology “CocoonTM “was acquired.

• During his leadership numerous strategic customer agreements were signed positioning Lonza as the number one CDMO for late phase Cell & Gene therapy projects.

• The last 3 years Andreas worked for Novartis, leading a global team identifying new strategic external partnerships, building a reliable global network of strategic manufacturing partners. His team completely redesigned and expanded the external autologous manufacturing footprint for KymriahTM from originally 1 to 4 commercial autologous manufacturing sites in Germany, Japan, Australia and China.

• In addition, the Viral Vector manufacturing for KymriahTM was switched to a suspension process reducing the cost by a factor 10-20.